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The MSCs are immature cells that can be found in nu-
merous different tissue types. In recent years, they 
have gained considerable attention, particularly with 
regard to their regenerative properties. Due to their 
paracrine activity, ability to migrate, adhesion and 
homing, MSCs currently appear to be the most relevant 
for therapeutic use. Numerous bioactive molecules se-
creted by MSCs exert paracrine effects and modulate 
many physiological processes, such as angiogenesis, 
immunomodulation and neuroprotection. Cell-cell com-
munication may be also mediated by extracellular vesi-
cles released from the cells. Due to these properties, 
MSCs have been widely studied for evaluation of their 
therapeutic benefits expected in the clinical applica-
tions. For effective tissue regeneration, transplanted 
MSCs have to exit the circulation and locate at the site 
of damage, which is possible because of their ability 
to migrate, adhere and engraft at the target site. Ac-
cumulating evidence suggests that MSCs recruitment 
from remote sites is similar to leukocytes’ migration. All 
of these biological features make MSCs highly investi-
gated stem cells and the most commonly used cells in 
regenerative medicine. Since environmental factors af-
fect the MSCs behavior, we discuss importance of oxy-
gen concentration as a one of the key factors affecting 
MSCs properties.
Key words: mesenchymal stem cells (MSCs), secretion, adhesion, mi-
gration, homing, cell therapy
Received: 21 October, 2019; revised: 17 December, 2019; accepted: 
19 December, 2019; available on-line: 28 December, 2019
✉e-mail: mmajka@cm-uj.krakow.pl (MM); marta.kot@uj.edu.pl (MK)
*Acknowlkedgements of Financial Support: 
The costs of the article published as a part of the 44th FEBS Con-
gress Kraków 2019 – From molecules to living systems block are 
financed by the Ministry of Science and Higher Education of the 
Republic of Poland (Contract 805/P-DUN/2019).
This work was supported by a research grant (STRAT-
EGMED2/265761/10/NCBR/2015) from the National Center for Re-
search and Development.
Abbreviations: MSCs, mesenchymal stem cells; EVs, extracellular 
vesicles; SDF-1α, cell-derived factor-1 alpha chemokine; MMP1, 
matrix metalloproteinase-1; ECM, extracellular matrix; VEGF, vas-
cular endothelial growth factor; HIF-1α, hypoxia-inducible factor 1 
alpha
INTRODUCTION
Mesenchymal stem cells (MSCs) are self-renewing, 
multipotent cells that can be isolated from nearly every 
tissue type (bone marrow, adipose tissue, umbilical cord, 
peripheral blood, placenta) (Zvaifler et al., 2000; Zuk et 
al., 2001; Najar et al., 2010; Fei et al., 2013; Heidari et 
al., 2013; Meier et al., 2013; Musialek et al., 2015; Musiał-
Wysocka et al., 2019a, Musiał-Wysocka et al., 2019b). A 
wide variety of tissue sources implies high heterogene-
ity of the isolated populations. Thus, MSCs are identified 
according to criteria established by ISTC in 2006, which 
have been summarized by Dominici and others (Domin-
ici et al., 2006). An important property of MSCs is their 
ability to secrete numerous factors involved in different 
processes that favor tissue remodeling, such as angiogen-
esis, immunomodulation or neuroprotection. All of these 
biological features, combined with ease of culture expan-
sion, make MSCs highly investigated stem cells and the 
most commonly used cells in regenerative medicine (Lee 
et al., 2010; Wang et al., 2012; Wei et al., 2013; Hare et 
al., 2017). It should be noted that despite general unified 
criteria outlined for MSCs, the cells isolated from differ-
ent tissues may vary in terms of their potential to dif-
ferentiate, proliferate or their profile of secreted factors. 
MSCs retain properties of the microenvironment from 
which they are derived in vivo (Mrozik et al., 2010).
The available data allow to distinguish some mecha-
nisms that are responsible for the therapeutic potential 
of mesenchymal stem cells. Positive effect of exogenous-
ly injected MSCs can be a result of both, the cell-cell 
interaction and the paracrine activity, such as:
• the ability to secrete factors initiating healing and tis-
sue regeneration
• horizontal material transfer (microvesicles, exosomes, 
mitochondria)
• the ability to reduce inflammation and regulate the 
immune response
• the capacity to differentiate/transdifferentiate into 
various cell lineages
• the ability to migrate and home in the site of injury
• fusion with the surrounding cells
One of the most important challenges of the current 
clinical use of MSCs is the comprehensive understanding 
of their biology, in particular the mechanism underlying 
the basis of their ability to regenerate damaged tissues. 
Despite accumulating evidence, the nature and functions 
of MSCs are not fully understood. Taking into consid-
eration all MSCs properties known so far, it is difficult 
to indicate only one of them that might be responsible 
for the therapeutic abilities of these cells. In this paper, 
we discuss the current understanding of MSCs proper-
ties that are inseparably connected with their regenera-
tive potential, such as the secretory activity and ability to 
migrate, adhere and home. It should be noted that the in 
vitro culture conditions under which the cells are exam-
ined differ from the in vivo environment, thus we have 
also considered the importance of oxygen concentration 
in MSCs investigations.
Vol. 66, No 4/2019
499–507
https://doi.org/10.18388/abp.2019_2895
500           2019M. Kot and others
THE MSCs’ PARACRINE EFFECT: SECRETOME AND 
MSCs-RELEASED VESICLES
MSCs secretome
The ability to secrete a variety of bioactive factors (cy-
tokines, chemokines, and growth factors) is one of the 
key activities of MSCs. The released molecules are in-
volved in interactions between MSCs or the surrounding 
microenvironment.
The spectrum of compounds produced and released 
by MSCs, generally referred to as the MSCs secretome, 
can be divided into several panels of factors involved 
in various biological processes, i.e. angiogenesis, immu-
nomodulation, neuroprotection, proliferation, migration, 
and chemotaxis (Fig. 1).
MSCs are tested in many preclinical and clinical stud-
ies as a promising approach for various therapies. They 
gained special attention in tissue regeneration, where the 
paracrine effect of MSCs is of particular interest. The 
ability to secrete biologically active molecules that can 
affect nearby cells is considered as key MSCs activity. 
It depends on the histological source of cells, the do-
nor age and impact of the surrounding microenviron-
ment. MSCs secretome composition can vary significant-
ly (Doorn et al., 2012). It is abundant in growth factors, 
cytokines and chemokines, therefore making MSCs a 
perfect source of a conditioned media for many studies 
concerning cell-free therapy (Praveen et al., 2019). Based 
on the composition and biological effects, we can divide 
the MSCs secretome into immunomodulating, neuropro-
tective, tissue remodeling and angiogenic.
Immunomodulation
MSCs’ properties of regulating the immune system are 
based not only on the particular surface molecules but 
also on secretion of many soluble factors. MSCs secrete 
both, the anti-inflammatory cytokines such as the trans-
forming growth factor β1 (TGF-β1), interleukin 13 (IL-
13), and pro-inflammatory cytokines such as IL1b, IL6, 
IL8 and IL9 (Vizoso et al., 2017). The importance of this 
equilibrium is presented with the results from a study 
with a mouse model of diabetics. It was shown that after 
application of conditioned media from the adipose tis-
sue, the MSCs balance in the pro- and anti-inflammato-
ry factors was restored. The IL-10 level was decreased, 
whereas the IL-1β, IL-6 and TNF-α levels were elevated 
in the dorsal root ganglia and the spinal cord (Brini et 
al., 2017).
Neuroprotection
The nervous system is characterized by a low regen-
eration potential. Therefore, studies that associate MSCs 
with improved nervous system recovery are substantial 
for the future therapies. In the beginning those func-
tions were correlated with the differentiation capacity 
of MSCs, but recent studies reveal the importance of 
the MSCs secretome in which we can find many neu-
roprotective and neuroregulatory factors (Teixeira et al., 
2013). Crigler and others (Crigler et al., 2006) discovered 
transcripts coding a brain-derived neurotrophic factor 
(BDNF) and nerve growth factor (β-NGF), after ana-
lyzing MSCs cDNA library. What is more, they corre-
late the nerve survival and outgrowth improvement with 
BDNF activity from co-culture experiments (Crigler et 
al., 2006). Further studies reveal that BDNF is a key fac-
tor secreted by MSCs from Wharton’s Jelly of the umbil-
ical cord (WJ-MSCs), which exclusively mediates axonal 
elongation in the rat cortical and hippocampal neurons 
(Martins et al., 2017).
Angiogenic
MSCs are widely studied in research concerning is-
chemic recovery. Angiogenic properties that promote 
sprouting of new blood vessels from preexisting ones 
seem to be a crucial regenerative feature of MSCs. Many 
studies confirm this activity owing to production of a va-
riety of factors, such as the vascular endothelial growth 
factor (VEGF-A), angiopoietins (ANGPTs), insulin-like 
growth factor-1 (IGF-1) or hepatocyte growth factor 
(HGF). VEGF is indicated as one of the most abundant 
proteins secreted by MSCs (Ferreira et al., 2018). The 
cell culture conditions seem to be crucial for the angio-
genic secretome properties. It was shown by Oskowitz 
et al. (2011) that a serum deprivation condition results 
in an increased expression of angiogenic factors, such 
as the VEGF-A, ANGPTs, IGF-1, and HGF. The an-
giogenic potential of the secretome was confirmed using 
an ex vivo rat aortic ring assay where media from serum 
deprived MSCs resulted in significantly longer vascular 
sprouts from rat aortic rings, in comparison to the un-
conditioned media. Apparently, the serum level is more 
relevant than the oxygen level – minor differences were 
observed in angiogenic properties in conditioned media 
from MSCs obtained under normal and hypoxic condi-
tion (Burlacu et al., 2013).
Tissue-remodeling and anti-fibrotic activity
Scar formation is an inseparable process of wound 
healing. MSCs have an ability to reduce accumulation 
of the extracellular matrix proteins. In the secretome 
from umbilical cord mesenchymal stem cells (UC-MSCs) 
in mice with fibrosis, 32 proteins were identified which 
downregulate expression of fibrotic factors, such as the 
metalloproteinases, collagens, TGF-β and Smad proteins. 
The milk fat globule EGF factor 8 (MFGE8) negatively 
regulates expression of TGFβR1 transforming growth 
factor β type 1 receptor, and therefore acts as an anti-fi-
brotic factor (An et al., 2017). The hypoxic environment 
promotes expression of cytoprotective factors in Akt1 
overexpressing BM-MSCs (Gnecchi et al., 2005).
MSCs-RELEASED VESICLES – HORIZONTAL MATERIAL 
TRANSFER AND CELL-TO-CELL COMMUNICATION
Extracellular vesicles (micro vesicles (MVs) and ex-
osomes) are small membrane vesicles (30–150 nm in 
Figure 1. Biological factors secreted by MSCs.
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diameter) of endocytic origin (Simpson et al., 2008). 
They arise from intracellular membrane of the cell by 
inward budding and are released from the cells into 
extracellular space after fusion with the plasma mem-
brane (Mears et al., 2004). During their formation, 
various transmembrane proteins and cytosolic com-
ponents are incorporated into membrane invagination 
and closed within the vesicles (van Niel et al., 2006). It 
has been found that MSCs can produce higher quanti-
ties of exosomes than other cells (Yeo et al., 2013). 
Extensive composition analysis of EVs released from 
MSCs has revealed occurrence of over 900 proteins. 
Examples of some identified proteins are depicted in 
Table 1. Among the set of cellular proteins, EVs may 
also contain a variety of lipids and different kinds of 
RNAs (mRNAs, microRNAs, tRNA, long noncoding 
RNAs) (http://exocarta.ludwig.edu.au). In general, the 
exosomes comprise tissue- or cell-type specific mol-
ecule composition depending on the tissue type in 
which they arise. In MSCs-derived EVs, CD73, CD90 
and CD105 antigens have been found that are charac-
teristic markers for MSCs (Dominici et al., 2006).
Recently, cell-cell communication mediated by ex-
tracellular vesicles has gained scientific interest. It is 
believed that a possible mechanism of intercellular 
communication through exosomes follows three path-
ways (Threy et al., 2001; Janowska-Wieczorek et al., 
2005; Bi et al., 2007; Camussi et al., 2010; Raposo & 
Stahl, 2019):
• juxtacrine signaling (contact-dependent signaling) – 
proteins occurring in the exosomal membrane can in-
teract with receptors in the membrane of target cells 
which activates intracellular signaling;
• ectodomain cleavage-based signaling – the exosomal 
membrane proteins are cleaved by proteases, released 
into extracellular space and then they become ligands 
which bind to the cell surface receptors;
• fusion – exosomes fuse with the cell membrane and 
release their contents into the recipient cell cytoplasm;
Several studies have reported that MSCs-derived ex-
osomes perform functions similar to those of MSCs, 
including repairing tissue and suppressing the inflam-
matory response. For this reason, MSCs-derived extra-
cellular vesicles seem to be an alternative to MSCs in 
medical applications. The cell-free therapy offers safe-
ty and low immunogenicity with the same regenerative 
capacities as the mother cells (Rager et al., 2016; Wil-
lis et al., 2018). The use of MSC-conditioned media 
without cell transplantation can promote tissue repair, 
which supports a potential role of EVs in regenerative 
medicine (Chen et al., 2014; Tsai et al., 2014).
FUSION – DIRECT CELL-CELL INTERACTION
One of the possible mechanisms of MSCs action may 
be fusion with the host cells. Cell fusion is an omnipres-
ent process in life and there is also evidence for fusion 
processes between stem cells and other neighboring cells.
The mechanism of stem cells fusion with other tis-
sue cells remains elusive as potentially therapeutic. The 
discussion is still ongoing, partially because of the fre-
quency of fusion events that are very rare. This is prob-
ably the main reason why we can find only a few papers 
describing the fusion process of MSCs. Several studies 
have reported that stem cells can fuse with cardiomyo-
cytes either by a permanent or partial cell fusion pro-
cess (Song et al., 2011; Kouris et al., 2012; Shadrin et al., 
2015). Shadrin et al. (2015) found that heterologous cell 
fusion promoted cardiomyocyte reprogramming back to 
a progenitor-like state, and showed that stem cell mito-
chondria were transferred into cardiomyocytes and per-
sisted in hybrids. The available data concerns mainly 
bone marrow derived MSCs (BM-MSCs) fusion. It has 
been reported that in the injured tissues, BM-MSCs can 
fuse in vivo with differentiated cells and form hybrids 
with a regenerative potential (Freeman et al., 2015). The 
bone marrow-derived hybrids were found in many or-
gans, such as the brain, retina, liver, muscle, and gut, 
where they participated in the reestablishment of tissue 
function (Acquistapace et al., 2011; Song et al., 2011; 
Kouris et al., 2012; Freeman et al., 2015).
MIGRATION AND HOMING – CRUCIAL PROCESSES IN 
MSCs-BASED THERAPY
Overcoming the endothelial barrier
Migration and homing of transplanted cells is a very 
complicated process that is still under investigation. De-
pending on the type of tissue source from which the 
MSCs are isolated, they have their unique, individual 
ability to migrate and home in a place of damage. These 
properties of MSCs are crucial for stem cell-based thera-
pies (Pendleton et al., 2013; Chen et al., 2014; Ullah et al., 
2015). The directional migration is not a random process 
but it occurs in response to factors (i.e. chemokines) 
termed as chemoattractants (Russo et al., 2014). The 
chemokine gradient released from the injured site re-
cruits transplanted MSCs and provokes them to directly 
migrate to the target site, which we generally refer to as 
chemotaxis (Yoon et al., 2016). The mechanism of MSCs 
migration may vary depending on the method of MSCs 
Table 1. Proteins identified in MSCs derived exosomes (data from http://exocarta.org).
Protein name Function
GAPDH, enolase 1, aldolase 1, PKM2, PGK1, PDIA3, GSTP1, DPP4, AHCY, TPL1, peroxiredoxins, 
P4HB, LDH, cyclophilin A, FASN, MDH1 and CNP Metabolic enzymes
MFGE8 and integrins Adhesion
HSP60, HSP70, HSPA5, CCT2 and HSP90 Heat-shock proteins
Annexins: I, II, IV, V, VI, VII and X1 Membrane trafficking and fusion
Syntenin, 14-3-3, G proteins, ARF1, CDC42, stomatin, SLC9A3R1, RALA, PDCD6, rack1, mucin 1, 
EHD1, RAN, PEBP1, MIF, RRAS2, RAC1, NRAS and EHD4 Signal transduction
Vimentin, actins, tubulins, cofilin 1, ezrin, profilin 1, moesin, radixin, myosin, perlecan, THBS1, 
IQGAP1, keratins, gelsolin, fibronectin 1 and LGALS3BP Cytoskeletal proteins
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administration. Local transplantation in spatial proximity 
to the injured site causes the cells to circumvent the long 
migration route through the vascular system. Intravenous 
(systemic) injection is favored but accompanied by more 
adverse events (e.g. pulmonary microembolism) (Boltze 
et al., 2015), and requires overcoming of the endothelial 
barrier. Many reports describe MSCs migration as highly 
resembling the leukocyte migration model. According to 
this scenario, systemic homing is a multistep process in-
volving rolling, crawling, adhesion and extravasation (dia-
pedesis). In the right spot the MSCs integrate with en-
dothelial cells, then overcome the endothelial basement 
membrane and the pericyte sheath, and then continue 
the interstitial migration towards the target site, that is 
navigated by the chemokine gradient (Laird et al., 2008; 
Teo et al., 2012; Schmidt et al., 2013; Ullah et al., 2015).
Factors involved in MSCs migration
Many chemokines and their receptors located on the 
cells’ surface are involved in the migration of MSCs and 
their homing at the target site (Cong et al., 2014). The 
inflammation and inflammatory processes play an im-
portant role in MSCs migration (Guan et al., 2018; Su et 
al., 2018). The stromal cell-derived factor-1 alpha chemo-
kine (SDF-1α) and its receptor (CXCR4) play a crucial 
role in the inflammatory process. The SDF-1α protein 
acts as a chemoattractant that mediates the recruitment 
of circulating MSCs that express the chemokine type 4 
receptor. It can also affect expression of other factors, 
such as the hepatocyte growth factor (HGF), stem cell 
factor (SCF) or Fms-related tyrosine kinase 3 ligand, by 
which cells are targeted to the place of damage (Kitaori 
et al., 2009; Baek et al., 2011; Wang et al., 2017; Su et al., 
2018). Several research groups have shown that growth 
factors, such as PDGF, TNF-α, and TGF-β1, have a 
strong chemoattractive effect on MSCs, which enhances 
their activity for directional migration (Wang et al., 2017). 
The studies conducted so far have shown that the dam-
aged tissues inside the body secrete numerous cytokines 
and express factors (chemoattractants) that guide MSCs 
to the site of damage.
It turns out that not only the source of stem cells and 
the number of passages, but also the method of cell iso-
lation and culture can have a relevant impact on the mi-
gratory potential of MSCs (Ode et al., 2011). It has been 
shown that an important issue to consider in the migra-
tion studies is the appropriate method of culture and 
medium supplementation, which allows the cells to opti-
mally grow and release factors that are pivotal during the 
MSCs migration process after their transplantation (Fu et 
al., 2019). The MMP matrix metalloproteinases that are 
necessary for efficiency migration and homing of MSCs 
play an important role in this process. MMPs belong to 
the proteolytic enzyme family that participates in degra-
dation of the basement membrane and extracellular ma-
trix (ECM) (Ries et al., 2007). The matrix metalloprotein-
ase-1 (MMP1), acting through the MMP1/PAR1 axis, 
causes decay of the interstitial collagen type I, II and III 
(Ho et al., 2009; Pan et al., 2014). It has been proven 
that upregulation of MMP1 expression leads to a high 
migration capacity of MSCs. In vitro studies have shown 
that knockdown of the MMP1 gene in MSCs results in 
inhibition of their migration capacity (Pan et al., 2014). 
Thus, cells with high MMP1 expression can be a valu-
able agent in clinical therapy affecting the possibility of 
cell engraftment at the target site.
During the MSCs in vitro culture, expression of factors 
involved in the migration process, such as CXCR4, may 
significantly decrease (Richter et al., 2017). To prevent 
this effect, the MSCs culture medium can be supple-
mented with cytokines that stimulate cells and preserve 
the potential of these cells for migration and homing. It 
was observed that addition of a cytokine cocktail con-
taining HGF or SCF to the culture medium resulted in 
improvement of directional migration of cells after ad-
ministration, as well as homing at the target site (Shi et 
al., 2007; Richter et al., 2017; Zhang et al., 2017). The 
oxygen culture conditions, i.e. hypoxia, may lead to an 
increase in the CXCR4 protein expression, which con-
sequently promotes and activates the migration process 
(Liu et al., 2010).
The process of stem cell migration depends on the 
microenvironment in which they are found. Factors se-
creted during tissue damage lead to the recruitment of 
the transplanted cells to this site, which is pivotal from 
the point of view of cellular therapies (Zhang et al., 
2017). The CD44 and CXCR4 proteins contribute signif-
icantly to this mechanism. The imprisonment of MSCs 
in the lungs, liver or spleen after intravenous infusion, 
constitutes a serious obstacle in cellular therapies. For 
this reason, therapies often use administration of cells di-
rectly at the site of injury (Russo et al., 2014). Neverthe-
less, stem cell properties allow for efficient migration and 
colonization at the site of injury. Initiation of the migra-
tion process can take place not only through mechanical 
stimuli (e.g. acute shear stress) but also by activation of 
receptors located at the MSCs surface, even through fac-
tors at a large distance from the target site (Kim et al., 
2013; Artemenko et al., 2016). Activated MSCs enter the 
appropriate signaling pathway which initiates the migra-
tion and adhesion processes, and adaptation to the ECM 
environment (Kim et al., 2013; Russo et al., 2014).
ADHESION MOLECULES – KEY PLAYERS IN MIGRATION 
AND HOMING OF MSCs
Several classes of cell adhesion molecules mediate in-
teraction between the cell and the substratum. Integrins 
are the most important among them. They participate in 
the cell-substratum and cell-cell interactions and are pre-
sent on almost all human cells (Albelda and Buck, 1990). 
The MSCs adhesion ability differs due to a different ex-
pression of certain integrins, such as α1, α 2, α3, α4, α5, 
α6, αV, β1, and β2 (Semon et al., 2010; Schmidt et al., 
2013). FACS analyses of functional characterization of 
MSCs described integrins αV, α1, α 2, α3, α5, and α6, 
but not α4, β, β4, β1, and β2 (Uder et al., 2018). MSCs 
may feature different adhesion properties depending on 
the tissue source, isolation and culture procedures (Barry 
& Murphy, 2004; Lin et al., 2006; Rui et al., 2010; Ren 
et al., 2015; Sanjurjo-Rodriguez et al., 2017; Uder et al., 
2018). Many studies demonstrated that β1 integrins are 
important for the intramyocardial trafficking of MSCs 
(Ip et al., 2008), and are crucial for the rolling and adhe-
sion of MSCs (Ruster et al., 2006).
Additionally, a study by Ip and others (Ip et al., 2008) 
suggested that the very late antigen-4 (VLA-4) and vas-
cular cell adhesion molecule-1 (VCAM-1) are expressed 
in MSCs (Ip et al., 2008). Among them, both the α4 
and β1 subunits play a crucial role in VLA-4 (the inte-
grin very late antigen) formation. Nitzsche and others 
and Chamberlain and others (Chamberlain et al., 2007; 
Nitzsche et al., 2017) describe the VLA-4 involvement in 
the endothelial rolling and apprehension at the inflam-
mation sites. Both authors cite the results of experi-
ments confirming the VCAM-1’s molecule role in firm 
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adhesion of MSCs. In many investigations, blocking the 
VCAM-1 or VLA-4 mediator, had significantly inhibited 
adhesion of MSCs to the endothelial cells (D’Ambrosio 
et al., 1998; Segers et al., 2006). These studies have veri-
fied that MSCs bind to endothelial cells in a P-selectin 
dependent manner. Ruster and others (Ruster’s et al., 
2006) showed that rolling of MSCs engages VLA-4/
VCAM-1 to provide firm adhesion to the endothelial 
cells (Ruster et al., 2006).
Moreover, the study of Ruster’s and others (Ruster’s et 
al., 2006) presents P-selectin involvement in the extrava-
sation cascade – as it has been proven in the MSCs ani-
mal model (Ruster et al., 2006). In this study, the P-selec-
tin deficient mice show a decrease in MSCs rolling along 
the walls of the blood vessels in the ear veins. Similar 
observations have been also made in the umbilical vein 
endothelial in vitro model, where MSCs rolling has de-
creased by neutralizing the P-selectin antibody. The L-se-
lectin expression is described as insignificant in the case 
of MSCs rolling on endothelium during the first stage 
of the recruitment process. In comparison to leukocytes, 
their expression on MSCs is much lower. Additionally, 
no expression of PECAM-1/CD31 (platelet/endothe-
lial cell adhesion molecule 1) has been found on MSCs 
(Bruder et al., 1998; Pittenger et al., 1999; Shur et al., 2002; 
Ruster et al., 2006), whereas occurrence of hematopoietic 
cell L-/E-selectin ligand, as well as NCAM1/CD56 (neu-
ral adhesion molecule 1), ICAM2/CD102 (intercellular 
adhesion molecule 2), MCAM/CD146 (melanoma cell 
adhesion molecule 2), and ALCAM/CD166 (activated 
leukocyte cell adhesion molecule), and ICAM1/CD54 
or ICAM3/CD50 has been shown. In addition, the P-
selectin antigens are not present on the surface of MSCs 
(Uder et al., 2018). In contrast to the Minguell and oth-
ers (Minguell et al., 2001) results, Krampera and others 
(Krampera et al., 2006) described expression not only of 
VCAM-1 and ALCAM, but also of ICAM-1 and ICAM-
3, and in addition that of endoglin/CD105 (Minguell et 
al., 2001; Krampera et al., 2006). As it has been previ-
ously mentioned, the existing differences in expression 
may be the consequence of experimental conditions, e.g. 
cell culture or their source. Segers et al. (2006) described 
a significant role of VCAM-1 in the animal rat model 
where they have stimulated the cardiac microvascular en-
dothelial cells and then they have monitored adhesion of 
MSCs to them (Segers et al., 2006). There is no proven 
role for the ICAM adhesion molecule in this model.
MOLECULAR MECHANISM OF MSCs 
ADHESION
Hypoxia, acute burns and injury 
of skeletal muscle, all trigger mo-
bilization of MSCs into peripheral 
blood (Mansilla et al., 2006; Ramirez 
et al., 2006; Rochefort et al., 2006). 
Differences in the cell adhesion 
molecule pattern, under different 
culture conditions, may be a start-
ing point for a discussion about the 
MSCs homing mechanism. At pre-
sent, there is no detailed and strong 
data describing MSCs transendothe-
lial migration. Because of existing 
differences in expression of the cell 
adhesion molecules between MSCs 
and well-described leukocytes, there 
is a need for further detailed inves-
tigation of MSCs adhesion, rolling, 
diapedesis and homing.
Regarding the mechanism of the homing process, ac-
tive surface molecules that are involved in MSCs – en-
dothelium adhesion are in the center of interest. They are 
believed to be involved in the principal mechanism of 
this process (Karp & Leng, 2009). As expression of cer-
tain chemokine receptors during the extravasation process 
is widely described, it is still unclear what their exact in-
volvement in this process is.
The presence of CCR2, CCR4, CCR7, CCR10, CXCR5, 
CXCR6, and CXCR4 is referred to in the literature 
(Wynn et al., 2004; Ringe et al., 2007; Andreas et al., 2014; 
Nitzsche et al., 2017). CCR2 participates in organ-specific 
homing (Belema-Bedada et al., 2008; Guo et al., 2013). 
In the Smith’s and others (Smith’s et al., 2012) research, 
chemokines: CXCL12, CXCL13, CXCL16, CCL11, and 
CCL22 are described as the ligands for the chemokine 
receptors: CXCR4, CXCR5, CXCR6, CCR3, and CCR4, 
which have been identified on the MSCs. In this study, 
the authors show a significantly enhanced transendothe-
lial migration across the bone marrow endothelial cells 
(Smith et al., 2012). On the other hand, in the research by 
Ip and others (Ip et al., 2007), CXCR4 is not directly in-
volved in the MSCs transendothelial migration, despite its 
proven expression on these cells. One of the reasons for 
such inconsistency in the role of specific cytokines may be 
rooted in the previously mentioned differences in experi-
mental conditions that vary between the studies, including 
cell culturing, type of medium, use of serum etc., as well 
as the isolation procedures (Uder et al., 2018).
Two signaling pathways are established to be of a great 
importance for the MSCs transendothelial migration. The 
phosphoinositide 3-kinase (PI3K)/Act pathway and phos-
phokinase C (PKC) pathway are described to have a sig-
nificant role in transendothelial migration. Among the 
different kinases involved in the MSCs signaling, the inte-
grin-linked kinase (ILK) is indicated. Its role as an intra-
cellular adapter in transmission of signals from the outside 
to the inside is discussed in the literature (Fig. 2) (Schmidt 
et al., 2006; Picinich et al., 2010; Widmaier et al., 2012).
THE INFLUENCE OF OXYGEN CONCENTRATION ON 
BIOLOGICAL PROPERTIES OF MSCs
The important issue in the investigation of biologi-
cal properties of MSC is the microenvironment (niche) 
in which the cells reside. One of the crucial factors is 
Figure 2. Molecular mechanism of MSCs activation and adhesion to activated en-
dothelium (according to Nitzsche et al., 2017, modified).
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oxygen concentration. It should be noted that the stand-
ard culture conditions in vitro including 21% O2 (21 
kPa/160 mmHg) are not identical to the in vivo environ-
ment, where oxygen concentration is significantly lower, 
about 2–9%, depending on the vascularization of the 
tissue and its direct contact with air (Brahimi-Horn & 
Pouyssegur, 2007; Ward, 2008). In the bone marrow, 
as a primary source of stem cells (both hematopoietic 
and mesenchymal), the concentration levels of O2 have 
been reported to range from 1.5% to 7% (Spencer et al., 
2014). A change in the oxygen level in an in vitro culture 
leads to alterations in metabolism (secretion of signal-
ing factors – growth factors and cytokines), proliferation 
(self-renewal), motility (adhesion, migration), and differ-
entiation potential. Consequently, the stemness potential 
can be lost.
A key factor that plays a crucial role in the regulation 
of stem cells metabolism is HIF-1α (hypoxia-inducible 
factor 1 alpha), a transcription factor involved in cellular 
response to low oxygen availability. HIF-1α is expressed 
by cells in a hypoxia environment and makes their me-
tabolism pathways similar to those occurring in an in vivo 
niche (Takubo et al., 2010). These facts explain why the 
oxygen level should be particularly taken into account 
during cell expansion for clinical applications.
The results of performed studies have revealed that 
hypoxia or HIF-1α stabilization have a beneficial effect 
on MSCs functions, such as proliferation, migration and 
adhesion, regardless of the tissue type of their origin. 
Low oxygen concentration favors maintenance of MSCs 
physiological properties, including proper expression of 
surface receptors involved in MSCs migration and adhe-
sion (Li et al., 2013; Choi et al., 2016). Song et al. (2009) 
presented that hypoxia promotes MSCs adhesion to my-
ocardium, thereby increasing their therapeutic potential 
(Song et al., 2009).
Many studies have also observed a hypoxia depend-
ent effect on the paracrine activity of MSCs. For exam-
ple, secretion of the vascular endothelial growth factor 
(VEGF) by AD-MSCs (adipose tissue derived-MSCs) is 
considerably enhanced under hypoxic conditions, where 
HIF-1α is more stable (Kang et al., 2014). VEGF, apart 
from its proangiogenic properties, also stimulates motil-
ity of stem cells (Yun et al., 2009).
There is also evidence that the proliferation capacity 
of MSCs is significantly improved in an environment 
with low oxygen concentration (Lech et al., 2016; Choi et 
al., 2017). Some studies suggest that a low oxygen level 
promotes self-renewal (asymmetric) divisions and inhibits 
symmetric ones, which precedes cell differentiation (Liu 
et al., 2012). The reduced oxygen content during stem 
cell culture has also a beneficial effect on their genomic 
stability. Lech and others (Lech at al., 2016) have showed 
that AD-MSCs cultured in reduced oxygen content (5% 
O2) maintain a correct karyotype profile compared to 
cells cultured in normoxia condition. In cultures grow-
ing under 21% O2 concentration numerous karyotyping 
abnormalities (i.e. chromosome polyploidy and haploid 
chromosomes) have been observed (Lech et al., 2016).
As detailed above, hypoxia promotes kinetic growth, 
genetic stability, proper pattern of MSC-specific surface 
markers, and increases cell lifespan, as well as exerts a 
positive effect on the paracrine activity and adhesion 
properties. Thus, conducting cell culture at the physio-
logical oxygen level seems to be more effective and safe 
in the case of MSCs used in regenerative therapies.
CONCLUSIONS
Mesenchymal stem cells are undoubtedly the future 
of regenerative medicine. The benefits of their clinical 
use have been proven in many studies, but development 
of safe and efficient therapy requires future investiga-
tions. The therapeutic potential is a result of their unique 
properties, including the paracrine activity, directional 
migration, adhesion and homing at the site of injury. A 
particular advantage of MSCs when compared to phar-
maceutical agents is their capability to secrete a cocktail 
of bioactive factors in response to circumstances and 
microenvironmental conditions. It should be noted that 
the culture conditions and the cell source have funda-
mental influence on biological properties of MSCs which 
should be considered in clinical use of MSCs.
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